These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 20580118)

  • 1. A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients.
    Davies JM; Dhruva NS; Walko CM; Socinski MA; Bernard S; Hayes DN; Kim WY; Ivanova A; Keller K; Hilbun LR; Chiu M; Dees EC; Stinchcombe TE
    Lung Cancer; 2011 Feb; 71(2):151-5. PubMed ID: 20580118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Okamoto I; Miyazaki M; Morinaga R; Kaneda H; Ueda S; Hasegawa Y; Satoh T; Kawada A; Fukuoka M; Fukino K; Tanigawa T; Nakagawa K
    Invest New Drugs; 2010 Dec; 28(6):844-53. PubMed ID: 19760364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
    Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer.
    Socinski MA; Weissman C; Hart LL; Beck JT; Choksi JK; Hanson JP; Prager D; Monberg MJ; Ye Z; Obasaju CK
    J Clin Oncol; 2006 Oct; 24(30):4840-7. PubMed ID: 17050869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC.
    Huang M; Gong Y; Zhu J; Qin Y; Peng F; Ren L; Ding Z; Liu Y; Cai C; Wang Y; Lu Y
    Invest New Drugs; 2020 Apr; 38(2):478-484. PubMed ID: 31231786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407.
    Govindan R; Bogart J; Stinchcombe T; Wang X; Hodgson L; Kratzke R; Garst J; Brotherton T; Vokes EE
    J Clin Oncol; 2011 Aug; 29(23):3120-5. PubMed ID: 21747084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
    Seiwert TY; Connell PP; Mauer AM; Hoffman PC; George CM; Szeto L; Salgia R; Posther KE; Nguyen B; Haraf DJ; Vokes EE
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):515-22. PubMed ID: 17255273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
    Socinski MA; Smit EF; Lorigan P; Konduri K; Reck M; Szczesna A; Blakely J; Serwatowski P; Karaseva NA; Ciuleanu T; Jassem J; Dediu M; Hong S; Visseren-Grul C; Hanauske AR; Obasaju CK; Guba SC; Thatcher N
    J Clin Oncol; 2009 Oct; 27(28):4787-92. PubMed ID: 19720897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase i study of 'dose-dense' pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma.
    Shen X; Denittis A; Werner-Wasik M; Axelrod R; Gilman P; Meyer T; Treat J; Curran WJ; Machtay M
    Radiat Oncol; 2011 Feb; 6():17. PubMed ID: 21324160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
    Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.
    Schuette WH; Gröschel A; Sebastian M; Andreas S; Müller T; Schneller F; Guetz S; Eschbach C; Bohnet S; Leschinger MI; Reck M
    Clin Lung Cancer; 2013 May; 14(3):215-23. PubMed ID: 23332288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients.
    Zhang GZ; Jiao SC; Meng ZT
    J Exp Clin Cancer Res; 2010 Apr; 29(1):38. PubMed ID: 20423465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial.
    Ardizzoni A; Tiseo M; Boni L; Vincent AD; Passalacqua R; Buti S; Amoroso D; Camerini A; Labianca R; Genestreti G; Boni C; Ciuffreda L; Di Costanzo F; de Marinis F; Crinò L; Santo A; Pazzola A; Barbieri F; Zilembo N; Colantonio I; Tibaldi C; Mattioli R; Cafferata MA; Camisa R; Smit EF
    J Clin Oncol; 2012 Dec; 30(36):4501-7. PubMed ID: 23109689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.
    Blais N; Camidge DR; Jonker DJ; Soulières D; Laurie SA; Diab SG; Ruiz-Garcia A; Thall A; Zhang K; Chao RC; Chow LQ
    Invest New Drugs; 2013 Dec; 31(6):1487-98. PubMed ID: 23963796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer.
    Kim C; Lee JL; Choi YH; Kang BW; Ryu MH; Chang HM; Kim TW; Kang YK
    Invest New Drugs; 2012 Feb; 30(1):306-15. PubMed ID: 20839031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
    Soria JC; Adjei AA; Bahleda R; Besse B; Ferte C; Planchard D; Zhou J; Ware J; Morrissey K; Shankar G; Lin W; Schutzman JL; Dy GK; Groen HJM
    Eur J Cancer; 2017 Nov; 86():186-196. PubMed ID: 28992562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seeking new options for the treatment of small-cell lung cancer.
    Socinski MA
    Lung Cancer; 2005 Oct; 50 Suppl 1():S25-6. PubMed ID: 16291430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
    Tagawa ST; Milowsky MI; Jeske S; Mazumdar M; Kung S; Sung M; Lehrer D; Matulich D; Selzer J; Wright JJ; Nanus DM
    Am J Clin Oncol; 2011 Oct; 34(5):443-8. PubMed ID: 20881475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer.
    Socinski MA; Raju RN; Stinchcombe T; Kocs DM; Couch LS; Barrera D; Rousey SR; Choksi JK; Jotte R; Patt DA; Periman PO; Schlossberg HR; Weissman CH; Wang Y; Asmar L; Pritchard S; Bromund J; Peng G; Treat J; Obasaju CK
    J Thorac Oncol; 2010 Dec; 5(12):1963-9. PubMed ID: 21102260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of vinflunine and pemetrexed in refractory solid tumors.
    Sanoff HK; Davies J; Walko C; Buie L; Chiu WK; Ivanova A; O'Neil B; Stinchcombe TE; Keller K; Dees EC
    Invest New Drugs; 2011 Feb; 29(1):131-6. PubMed ID: 19830387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.